|
Index of reports
> Cases resulting in disability (20)
> Cases with Dyspnoea (3)
Below is the selection of adverse event reports related to Requip (Ropinirole) that includes cases resulting in disability where reactions include dyspnoea.
Adverse event in 73 year old male receiving Requip (Ropinirole)
Reported by a consumer/non-health professional from United States on 2007-06-15
Patient: 73 year old male
Adverse reactions / side effects: Dyspnoea, Dyspnoea Exertional, Interstitial Lung Disease
Adverse event resulted in: death, life threatening event, hospitalization, disablity
Suspect drug(s):
Requip (Ropinirole)
Other drugs received by patient: Heart Medication
Adverse event in 73 year old male receiving Requip (Ropinirole)
Reported by a consumer/non-health professional from United States on 2007-06-14
Patient: 73 year old male
Adverse reactions / side effects: Dyspnoea, Dyspnoea Exertional, Interstitial Lung Disease
Adverse event resulted in: death, life threatening event, hospitalization, disablity
Suspect drug(s):
Requip (Ropinirole)
Other drugs received by patient: Heart Medication
Adverse event in female receiving Requip (Ropinirole)
Reported by a consumer/non-health professional on 2007-05-02
Patient: female, weighing 85.0 kg (187.0 pounds)
Adverse reactions / side effects: Intercostal Neuralgia, Drug Effect Decreased, Dyspnoea, Magnesium Deficiency, Muscular Weakness, Hyperuricaemia, Hypercholesterolaemia, Anxiety, Spinal Osteoarthritis, Thyroid Neoplasm, Feeling Abnormal, Intervertebral Disc Displacement
Adverse event resulted in: hospitalization, disablity
Suspect drug(s):
Madopar LT
Dosage: 400-500 mg levodopa/benserazide
Administration route: Oral
Indication: Restless Legs Syndrome
Start date: 2003-08-01
End date: 2004-01-01
Madopar LT
Dosage: 200 mg levodopa/benserazide
Administration route: Oral
Start date: 2004-01-01
End date: 2005-01-01
Requip
Administration route: Oral
Indication: Restless Legs Syndrome
Start date: 2005-02-01
End date: 2005-06-01
Restex Retard
Dosage: at night
Administration route: Oral
Indication: Restless Legs Syndrome
Start date: 2003-08-01
End date: 2004-01-01
Sifrol
Administration route: Oral
Indication: Restless Legs Syndrome
Start date: 2005-07-01
End date: 2006-03-01
Sifrol
Indication: Extrapyramidal Disorder
Valoron
Dosage: at night
Administration route: Oral
Indication: Restless Legs Syndrome
Start date: 2004-01-01
End date: 2005-01-01
Other drugs received by patient: Magnerot Classic; Valoron; Ceferro
|
